DAVID TANIS: Open Payments
NPI 1598372807 · ANTHEM, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,830 in 114 payments from 15 companies in 2025. Trend: 2023 $1,787 · 2024 $2,748 · 2025 $1,830
Food & beverage: $1,830
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 30 | $405 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $305 |
| ABBVIE INC. | 18 | $266 |
| Alkermes, Inc. | 9 | $173 |
| Lundbeck LLC | 8 | $137 |
| Corium, LLC | 6 | $90 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| Supernus Pharmaceuticals, Inc. | 5 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| E.R. Squibb & Sons, L.L.C. | 3 | $57 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, REXULTI, ARISTADA, Azstarys, Auvelity, Qelbree.
Industry payments across AZ — which companies pay providers there.
